Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article
Madhavan M. et al, (2022), EBioMedicine
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Journal article
Padron-Regalado E. et al, (2022), Sci Rep, 12
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.
Journal article
Ng WM. et al, (2022), Cell Host Microbe
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Journal article
Jenkin D. et al, (2022), Lancet Microbe
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies
Preprint
Ng W. et al, (2022)
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnol Bioeng, 119, 48 - 58
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Sci Rep, 11
Stability of chimpanzee adenovirus vectored vaccines (Chadox1 and chadox2) in liquid and lyophilised formulations
Journal article
Berg A. et al, (2021), Vaccines, 9
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Sci Rep, 11
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.
Journal article
Minassian AM. et al, (2021), Med (N Y), 2, 701 - 719.e19
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nature medicine
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.
Journal article
LAMBE T. et al, (2020), Nature Medicine
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2020), Nat Med
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2020), Lancet